AstraZeneca: Stifel confirms 'buy' rating

(CercleFinance.com) - Stifel maintains its Buy rating on AstraZeneca shares, with an unchanged target price of 14,100 pence.


As a reminder, AstraZeneca published its quarterly results yesterday, with revenues up 21%, while operating expenses, and in particular SG&A costs, rose at a more moderate pace. Core operating profit and EPS were up 27%.

With increased visibility for Q4, this has led to an upward revision of forecasts, with high expected growth for revenues and profits.

Thus, AstraZeneca enters 2025 with solid commercial momentum and a busy agenda in terms of clinical results, Stifel points out.

The laboratory will nevertheless have to contend with headwinds (Symbicort in the US, Brilinta, Farxiga in the US and VBP in China), but also around Dato-Dxd and the survey in China.

To a certain extent, we also lack visibility on the level of Capex required to achieve our 2030 targets, the broker adds.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.